Bluebird bio Inc (NASDAQ:BLUE) shares, rose in value, with the stock price down by -1.13% to the previous day’s close as strong demand from buyers drove the stock to $0.91.
Actively observing the price movement in the last trading, the stock closed the session at $0.92. The value of beta (5-year monthly) was 0.80. Referring to stock’s 52-week performance, its high was $5.53, and the low was $0.88. On the whole, BLUE has fluctuated by -23.96% over the past month.
With the market capitalization of Bluebird bio Inc currently standing at about $175.88 million, investors are eagerly awaiting this quarter’s results, scheduled for May 07, 2024 – May 13, 2024.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that BLUE’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of BLUE currently trading nearly -18.56% and -27.36% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 34.59, while the 7-day volatility ratio is showing 9.43% which for the 30-day chart, stands at 9.22%. Furthermore, Bluebird bio Inc (BLUE)’s beta value is 0.82, and its average true range (ATR) is 0.11.
A comparison of Bluebird bio Inc (BLUE) with its peers suggests the former has fared considerably weaker in the market. BLUE showed an intraday change of -1.13% in last session, and over the past year, it shrunk by -75.14%%.
Data on historical trading for Bluebird bio Inc (NASDAQ:BLUE) indicates that the trading volumes over the past 3 months, they’ve averaged 8.39 million. According to company’s latest data on outstanding shares, there are 192.74 million shares outstanding.
Nearly 1.51% of Bluebird bio Inc’s shares belong to company insiders and institutional investors own 61.92% of the company’s shares. The stock has fallen by -33.88% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the BLUE stock heading into the next quarter.
